Cannabidiol shows promise against superbugs by Angus Liu Monday, June 24, 2019 Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.
Development Advice for CBD Products Presented by: Rho Wednesday, April 24, 2019 What does it take to bring a CBD product to market for an unmet medical need?
Corbus nets over 600 cannabinoid compounds, to test 1-2 per year by Conor Hale Thursday, September 20, 2018 Corbus bought over 600 compounds from Jenrin Discovery to fuel 1 to 2 new clinical programs in inflammatory and fibrotic diseases annually from 2020.
Auxly Cannabis to acquire CRO KGK for $12.3M by Joseph Keenan Wednesday, August 29, 2018 Auxly Cannabis Group is buying KGK in a cash and stock deal worth $12.3 million.
GB Sciences to test cannabis-based therapies in humans by Angus Liu Tuesday, July 18, 2017 GB Sciences will soon start human testing of three cannabis-derived formulations for Parkinson's, chronic pain and cardiovascular diseases.
Ophthalmic CRO Ora kept in ocular clinical trial pact with Axim by Angus Liu Wednesday, March 29, 2017 Axim Biotechnologies, which explores medical uses of cannabis, has decided to continue contracting Ora to manage its drug R&D activities and clinical trials on glaucoma and dry eye.
GW Pharma nears all-time highs on 3rd set of positive pivotal data by Stacy Lawrence Monday, September 26, 2016 GW Pharma has clocked a third set of positive pivotal trial data, which makes it an even more attractive potential purchase.
GW Pharma gains on M&A rumor as it preps for FDA submission by Stacy Lawrence Wednesday, September 7, 2016 GW Pharmaceuticals gained about $500 million in market cap on rumors that it may soon be acquired.
